Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 4.07 is 59% below its 5-year average of 10.03, near the low end of its 5-year range (1.99–23.48).
As of the fiscal period ended Tuesday, June 30, 2026. 35.93% above its 12-month average of 3.00.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.07.
CURRENT RATIO
4.07
CURRENT RATIO AVG TTM
3.00
CURRENT RATIO AVG 3Y
7.21
CURRENT RATIO AVG 5Y
10.03
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+35.93%
CURRENT VS 3Y AVG
-43.56%
CURRENT VS 5Y AVG
-59.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.74
median of 856 covered companies
CURRENT VS SECTOR MEDIAN
+9.02%
vs the sector median at left
Prelude Therapeutics Incorporated
Market Cap
$211.79M
Current Ratio
4.07
TTM Avg
3.00
3Y Avg
7.21
5Y Avg
10.03
Market Cap
$214.30M
Current Ratio
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$208.47M
Current Ratio
10.89
TTM Avg
11.84
3Y Avg
8.89
5Y Avg
15.32
Market Cap
$216.82M
Current Ratio
344.31
TTM Avg
177.51
3Y Avg
95.19
5Y Avg
76.57
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $211.79M | 4.07 | 3.00 | 7.21 | 10.03 |
| Compugen Ltd. (CGEN)vs › | $211.33M | 5.72 | 5.91 | 5.85 | 7.15 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.30M | 5.36 | 6.17 | 11.50 | 11.99 |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 6.50 | 4.21 | 3.36 | 3.03 |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.63M | 4.10 | 3.67 | 3.34 | 3.14 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.47M | 10.89 | 11.84 | 8.89 | 15.32 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | 344.31 | 177.51 | 95.19 | 76.57 |
| Alector, Inc. (ALEC)vs › | $206.05M | 5.26 | 3.62 | 4.54 | 4.95 |
| Sionna Therapeutics, Inc. (SION)vs › | $205.81M | 20.05 | 17.55 | 12.54 | 12.54 |
Current Ratio
4.07
Quick Ratio
4.07
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 4.07 |
| 2026-03-31 | 2.03 |
| 2025-12-31 | 1.99 |
| 2025-09-30 | 3.21 |
| 2025-06-30 | 3.68 |
| 2025-03-31 | 5.18 |
| 2024-12-31 | 5.30 |
| 2024-09-30 | 7.04 |
| 2024-06-30 | 7.83 |
| 2024-03-31 | 11.64 |
| 2023-12-31 | 10.79 |
| 2023-09-30 | 13.91 |
| 2023-06-30 | 17.13 |
| 2023-03-31 | 8.91 |
| 2022-12-31 | 9.42 |
| 2022-09-30 | 10.52 |
| 2022-06-30 | 15.72 |
| 2022-03-31 | 16.80 |
| 2021-12-31 | 15.37 |
| 2021-09-30 | 16.57 |
| 2021-06-30 | 23.48 |
| 2021-03-31 | 29.38 |
| 2020-12-31 | 19.41 |
| 2020-09-30 | 20.96 |
| 2020-06-30 | 5.44 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 4.18 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
